noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

NFWF - National Fish and Wildlife[...]

NFWF and Partners Announce $5 Million in Grants to Restore Forests and[...]
Vermont Agency of Agriculture,[...]

Agriview - September 2026
Cape Cod Hospital

That funny feeling in your chest could be heart palpitations

Healthcare

Lexaria Bioscience Corp.

09/01/2026 | Press release | Distributed by Public on 09/01/2026 07:16

Material Event (Form 8-K)

Item 8.01 Other Events

Receipt of Australian R & D Tax Incentive Credit

On August 28, 2026, Lexaria (AU) Pty Ltd, the wholly-owned subsidiary of Lexaria Bioscience Corp. which holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in the territory of Australia, received a tax credit in the amount of AUD$3,666,611.98 (USD$2.6M), from the Australian Tax Office (the "Credit") in connection with the research and development costs associated with its Australian clinical study GLP-1-H24-4.

The Credit has been deposited into the Australian bank account of Lexaria (AU) Pty Ltd for the intended purpose of pursuing additional research and development opportunities in Australia.

Lexaria Bioscience Corp. published this content on September 01, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 01, 2026 at 13:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]